In the GCC region, the vast majority of BC cases (82.1% to 93%) have invasive ductal carcinoma (IDC) (7, 8), and 19.2% to 29.5% have HER2 overexpression (7, 8, 12), while 14.3% to 26.9% have triple-negative BC (TNBC) (7, 8). Here, ERBB2 is linked to breast cancer.